BioTuesdays: Oramed sees value creating events through 2016

//BioTuesdays: Oramed sees value creating events through 2016

BioTuesdays: Oramed sees value creating events through 2016

Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about Oramed’s progress and future advances.

“Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications”

biotuesdays.com/2015/12/01/oramed-sees-value-creating-events-through-2016/

2018-05-30T18:41:26+00:00 Categories: 媒体报导|